10.01.05
Indication: Blood pressure
Source: Br J Nutr, August 2005;94:84-91 (via Medical News Today).
Research: The single-blinded, placebo-controlled study was conducted amongst 131 subjects with high-normal blood pressure or mild hypertension to investigate the efficacy of hydrolyzed casein containing two dairy peptides, isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) in reducing blood pressure. (This active ingredient, known as AmealPeptide, has been added to a new mini drink launched under the Flora/Becel pro.activ brand, which is targeted at people following a healthy diet to control their blood pressure.)
Results: The study demonstrated that volunteers consuming a daily dose of IPP and VPP of 1.8, 2.5 or 3.6 mg experienced a dose dependent decrease in systolic blood pressure (SBP) compared to placebo. In subjects receiving 1.8 mg of IPP and VPP, a significant decrease in SBP was observed at 6 weeks, and in subjects receiving either 2.5 or 3.6 mg, a significant decrease in SBP was recorded at both 3 and 6 weeks. The antihypertensive effect was greater in subjects with mild hypertension than in subjects with high-normal blood pressure.
Source: Br J Nutr, August 2005;94:84-91 (via Medical News Today).
Research: The single-blinded, placebo-controlled study was conducted amongst 131 subjects with high-normal blood pressure or mild hypertension to investigate the efficacy of hydrolyzed casein containing two dairy peptides, isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) in reducing blood pressure. (This active ingredient, known as AmealPeptide, has been added to a new mini drink launched under the Flora/Becel pro.activ brand, which is targeted at people following a healthy diet to control their blood pressure.)
Results: The study demonstrated that volunteers consuming a daily dose of IPP and VPP of 1.8, 2.5 or 3.6 mg experienced a dose dependent decrease in systolic blood pressure (SBP) compared to placebo. In subjects receiving 1.8 mg of IPP and VPP, a significant decrease in SBP was observed at 6 weeks, and in subjects receiving either 2.5 or 3.6 mg, a significant decrease in SBP was recorded at both 3 and 6 weeks. The antihypertensive effect was greater in subjects with mild hypertension than in subjects with high-normal blood pressure.